NCT02987374 (SLVP023) is a Phase 4 clinical trial of 2011-2012 Fluzone IIV3 (IM) in Influenza, sponsored by Stanford University.

Who is sponsoring NCT02987374?

NCT02987374 is sponsored by Stanford University.

What drugs are being tested in NCT02987374?

Interventions in NCT02987374: 2011-2012 Fluzone IIV3 (IM).

Is NCT02987374 still recruiting?

NCT02987374 is currently completed. Last updated 3 April 2017.

Are results published for NCT02987374?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-04-03 · How we verify

NCT02987374: SLVP023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization

Completed Phase 4 Results posted Last updated 3 April 2017

What this trial tests

Phase 4 trial testing 2011-2012 Fluzone IIV3 (IM) in Influenza in 10 participants. Completed in 1 December 2012.

Timeline

1 May 2012

Primary endpoint
1 December 2012

1 December 2012

Quick facts

Lead sponsor	Stanford University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	1 May 2012
Primary completion	1 December 2012
Estimated completion	1 December 2012

Drugs / interventions tested

2011-2012 Fluzone IIV3 (IM) — full drug profile →

Conditions studied

Influenza — all drugs for Influenza →

Sponsor

Stanford University

Who can join

Adults 18 to 30, any sex, with Influenza. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants Who Received Influenza Vaccine
Time frame: Day 0 to 180 post-immunization

Sponsor's own description

The purpose is to investigate B-cell response to the trivalent Influenza Vaccine (TIV) in healthy young adults by vaccinating participants and obtaining blood samples at designated time points before and after vaccination.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Signatures of selection in the human antibody repertoire: Selective sweeps, competing subclones, and neutral drift.
Horns F, Vollmers C, Dekker CL, Quake SR. · · 2019 · cited 65× · PMID 30622180 · DOI 10.1073/pnas.1814213116

Verify or expand the search:

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02987374 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 3 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02987374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing